Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 714-721    DOI: 10.12892/ejgo4631.2019
Review Previous articles | Next articles
A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer
S. Dierckxsens1, B. Geerinckx1, M.T. Huizing1, W.A.A. Tjalma1, *()
1Multidisciplinary Breast Clinic Antwerpen, Antwerp University Hospital - University of Antwerp, Edegem, Belgium
Download:  PDF(653KB)  ( 188 ) Full text   ( 8 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Background: The sentinel lymph node biopsy (SLNB) is the standard procedure to assess the lymph node status in women with early stage breast cancer. It is uncertain whether SLNB is useful after neo-adjuvant chemotherapy (NACT) given to women with locally advanced breast cancer. Materials and Methods: A literature search was conducted over a timeframe of 22 years (1994-2016). Forty-three studies evaluating the feasibility and accuracy of SLNB after NACT were identified. Results: The pooled identification rate was 88% and the pooled false negative ratio was 12%. Conclusion: SLNB could be considered as a standard procedure after NACT.

Key words:  Breast cancer      Neo-adjuvant chemotherapy      Sentinel lymph node biopsy      Axillary clearance      Morbidity      SLN      Survival     
Published:  10 October 2019     
*Corresponding Author(s):  W.A.A. TJALMA     E-mail:  Wiebren.Tjalma@uza.be

Cite this article: 

S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4631.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/714

[1] Polyana Barbosa Silva, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Cândido Murta. Phenotypic differences of tecidual TDCs obtained from breast cancer mice[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 689-698.
[2] Huifen Zhen, Fan Guo, Xiaojun Zhang, Miaomiao Jia, Haibo Yang, Yarong Yao, Yuandong Li, Jinnan Gao. The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 785-789.
[3] Katselashvili Lika, Jokhadze Natia, Katcharava Margarita, Vardiashvili Nino. Breast Cancer Metastatic to Vulva - a Case Report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 845-848.
[4] Ji Geun Yoo, Hae Nam Lee, Sung Jong Lee, Jin Hwi Kim, Yong Seok Lee, Ahwon Lee, Soo Young Hur, Keun Ho Lee. Germline BRCA2 mutation is associated with greater progression-free survival in korean women with advanced high-grade serous ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 675-680.
[5] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[6] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[7] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[8] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[9] Isao Otsuka. Clear cell carcinoma of the vagina followed by breast cancer in a patient without prenatal diethylstilbestrol exposure[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 638-639.
[10] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[11] Luca Roncati, Maria Vadalà, Pepe Valentina, Veronica Corazzari, Beniamino Palmieri. Genomic profiling in gynaecological oncology: the future is now![J]. European Journal of Gynaecological Oncology, 2020, 41(3): 323-325.
[12] Lindsey Buckingham, Lori Cory, Colleen Brensinger, Xiaochen Zhang, Robert A. Burger, Fiona Simpkins, Emily M. Ko. Epidemiologic profile of benign versus oncologic gynecology populations: similar procedures, different patients[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 396-401.
[13] Xiaofeng Xu, Xuan Zhou, Yijin Wang, Tao Liu, Jian Fu, Qian Yang, Jun Wu, Huaijun Zhou. Survival-associated transcriptome analysis in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 455-461.
[14] M.E. Căpîlna, B. Szabo, J. Becsi, M. Morariu, M. Gheorghe, S.L. Kiss, B. Moldovan. Surgical complications and survival after pelvic exenteration: our experience following 60 procedures[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 171-175.
[15] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
No Suggested Reading articles found!